NCT06653946 is a Phase 4 clinical trial of Alteplase in Ischemic Stroke, sponsored by Kafrelsheikh University.

Who is sponsoring NCT06653946?

NCT06653946 is sponsored by Kafrelsheikh University.

What drugs are being tested in NCT06653946?

Interventions in NCT06653946: Alteplase, Alteplase.

What condition does NCT06653946 study?

NCT06653946 studies Ischemic Stroke, Alteplase Adverse Reaction.

Is NCT06653946 still recruiting?

NCT06653946 is currently recruiting now. Last updated 29 October 2024.

Last reviewed 2024-10-29 · How we verify

NCT06653946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Recruiting now Phase 4 Last updated 29 October 2024

What this trial tests

Phase 4 trial testing Alteplase in Ischemic Stroke in 716 participants. Currently enrolling.

Timeline

1 July 2022

Primary endpoint
1 July 2024

1 November 2024

Quick facts

Lead sponsor	Kafrelsheikh University
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	716
Start date	1 July 2022
Primary completion	1 July 2024
Estimated completion	1 November 2024
Sites	1 location across Egypt

Drugs / interventions tested

Alteplase (ALTEPLASE) — full drug profile →
Alteplase (ALTEPLASE) — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →
Alteplase Adverse Reaction — all drugs for Alteplase Adverse Reaction →

Sponsor

Kafrelsheikh University

Who can join

Adults 18 to 75, any sex, with Ischemic Stroke or Alteplase Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A multi-center study on the predictors of different subtypes of hemorrhagic transformation of brain infarction after thrombolysis in atrial fibrillation patients presented with embolic stroke.
Ahmed SR, Zeinhom MG, Ebied AAMK, Kamel IFM, et al · · 2025 · cited 7× · PMID 40325067 · DOI 10.1038/s41598-025-97968-3

Verify or expand the search:

Other trials of Alteplase

Trials testing the same drug.

NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism · recruiting
NCT07360717 — To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion · NA · completed
NCT06621121 — A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Strok · recruiting
NCT06194968 — Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study · recruiting

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Kafrelsheikh University trials

Trials by the same sponsor.

NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07433920 — L-PRF Versus Sticky Bone Grafting of the Jumping Gap in AI-assisted Computer-Guided Socket Shield Immediate Implantation · NA · recruiting
NCT07368348 — Evaluation of Internal Nasal Splint-Supported Free Graft Versus Nasoseptal Flap for Endoscopic Skull Base Repair in Cere · NA · recruiting
NCT07348094 — Guided Lateral Sinus Lifting Using Autologous Serum Albumin/Platelet-Rich Fibrin · NA · recruiting
NCT07359144 — Pilates Exercises on Nonspecific Low Back Pain in Postnatal Women · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06653946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kafrelsheikh University
Last refreshed: 29 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06653946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing